Previous close | 3.5500 |
Open | 3.4900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 75.00 |
Expiry date | 2025-01-17 |
Day's range | 3.4900 - 3.5800 |
Contract range | N/A |
Volume | |
Open interest | 1.88k |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Facing accusations of greed, the pay packages of FTSE CEOs are back in the headlines. But our writer takes a more relaxed view, on one condition. The post I don’t care how much FTSE bosses are paid as long as they make me rich! appeared first on The Motley Fool UK.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).